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ABSTRACT 
 
Rationale: Individuals with naturally occurring loss-of-function PCSK9 mutations experience 
reduced blood low-density lipoprotein cholesterol (LDL-C) levels and protection against 
cardiovascular disease. 
 
Objective: The goal of this study was to assess whether genome editing using a clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system can efficiently 
introduce loss-of-function mutations into the endogenous PCSK9 gene in vivo. 
 
Methods and Results: We used adenovirus to express Cas9 and a CRISPR guide RNA targeting 
Pcsk9 in mouse liver, where the gene is specifically expressed. We found that within three to four 
days of administration of the virus, the mutagenesis rate of Pcsk9 in the liver was as high as >50%. 
This resulted in decreased plasma PCSK9 levels, increased hepatic LDL receptor levels, and 
decreased plasma cholesterol levels (by 35%–40%) in the blood. There was no evidence of 
significant off-target effects. 
 
Conclusions: Genome editing with the CRISPR-Cas9 system can be used to disrupt the Pcsk9 gene 
in vivo with high efficiency and reduce blood cholesterol levels. This approach may have 
therapeutic potential for the prevention of cardiovascular disease in humans. 
 
KEYWORDS 
 
Coronary disease; gene therapy; lipoprotein; molecular biology; prevention 
 
ABBREVIATIONS 
 
LDL, low-density lipoprotein cholesterol; CHD, coronary heart disease; PCSK9, proprotein convertase 
subtilisin/kexin type 9; LDLR, low-density lipoprotein receptor; CRISPR, clustered regularly interspaced 
short palindromic repeats; Cas, CRISPR-associated; PAM, protospacer-adjacent motif; NHEJ, non-
homologous end joining; GFP, green fluorescent protein; ELISA, enzyme-linked immunosorbent assay. 
 
INTRODUCTION 
 
Among the best-established causal risk factors for cardiovascular disease, the leading cause of death 
worldwide, is the blood concentration of low-density lipoprotein cholesterol (LDL-C), and 
pharmacological therapy that reduces LDL-C levels—namely the statin drugs—has proven the most 
effective means of reducing the risk of coronary heart disease (CHD). Yet even with the use of statin 
therapy, there remains a large residual risk of CHD, and a substantial proportion of patients are intolerant 
of statin therapy. Thus, there is a critical need to develop new strategies for the reduction of LDL-C. 
 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for 
the prevention of CHD. A gene specifically expressed in and secreted from the liver, and believed to 
function primarily as an antagonist to the LDL receptor (LDLR), PCSK9 was originally identified as the 
cause of autosomal dominant hypercholesterolemia in some families, with gain-of-function mutations in 
the gene driving highly elevated LDL-C levels and premature CHD.1 In subsequent studies, individuals 
with single loss-of-function mutations in PCSK9 were found to experience a significant reduction of both 
LDL-C levels (~30%–40%) as well as CHD risk (88%).2,3 Notably, even individuals with two loss-of-
function mutations in PCSK9—resulting in ~80% reduction in LDL-C levels—appear to suffer no 
adverse clinical consequences.4,5 This observation suggests that therapies directed against PCSK9 would 
offer cardiovascular benefit without any accompanying undesirable effects. Just 10 years after the 
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discovery of PCSK9, PCSK9-targeting monoclonal antibodies are being evaluated in clinical trials.6 Yet 
even if these antibody-based drugs prove effective, their effects on LDL-C are short-lived, and patients 
will have to receive injections of the drugs every few weeks, which will limit their use as preventative 
therapy.  
 
The ability to permanently alter the human genome has been made possible by the technology now 
commonly known as “genome editing.” Recently published clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR‐associated (Cas) systems use Streptococcus pyogenes Cas9 
nuclease that is targeted to a genomic site by complexing with a synthetic guide RNA that hybridizes a 
20-nucleotide DNA sequence (protospacer) immediately preceding an NGG motif (PAM, or protospacer-
adjacent motif) recognized by Cas9.7,8 CRISPR-Cas9 generates a double-strand break that is usually 
repaired by non-homologous end-joining (NHEJ), which is error-prone and conducive to frameshift 
mutations resulting in knock-out alleles of genes. 
 
In light of the observed high efficiencies of CRISPR-Cas9 in mammalian cells in vitro,7,8 we assessed 
whether CRISPR-Cas9 can be used to disrupt the mouse Pcsk9 gene in vivo with high efficiency. A proof 
of principle that the gene can be targeted in mammalian hepatocytes in vivo would suggest that the 
approach might be viable in humans. 
 
METHODS 
 
An expanded Methods section is available in the Online Supplement. Candidate guide RNAs were 
designed to target exon 1 or exon 2 of the Pcsk9 gene, transfected into 3T3-L1 cells, and assessed for 
efficacy with Surveyor assays. Adenoviruses either expressing green fluorescent protein (GFP) or 
coexpressing Cas9 plus a guide RNA targeting Pcsk9 exon 1 (CRISPR-Pcsk9) were generated. In one 
experiment, a total of four 11-week-old male C57BL/6 mice were used, two each for the GFP and 
CRISPR-Pcsk9 adenoviruses. In a second, more comprehensive experiment, a total of 15 5-week-old 
female C57BL/6 mice were used, five each for the GFP and CRISPR-Pcsk9 adenoviruses and five with 
no virus. Following the virus administration, after three days (in the first experiment) or four days (in the 
second experiment) the mice were sacrificed after overnight fasting, and the livers were harvested and 
terminal blood samples collected. For the second experiment, to test the null hypotheses that each of four 
plasma analytes—PCSK9, triglyceride, cholesterol, and ALT—did not differ among the groups of mice 
(N = 5 for each group), P values were determined by the Kruskal-Wallis test performed on the set of the 
three groups. For each analyte for which the Kruskal-Wallis P was statistically significant, the Mann-
Whitney U test was performed between each pair of groups within the set of three groups. 
 
RESULTS 
 
We initially screened candidate CRISPR guide RNAs targeting sequences in exon 1 and exon 2 of the 
mouse Pcsk9 gene in 3T3-L1 cells. We found that the guide RNA targeting exon 1 displayed ~50% 
mutagenesis at the on-target site in Pcsk9, as judged by the Surveyor assay (Figure 1A, Supplemental 
Figure 1). We made an adenovirus coexpressing Cas9 and this guide RNA (CRISPR-Pcsk9), using an 
adenovirus expressing GFP as a control. 
 
In a pilot experiment, the CRISPR-Pcsk9 virus and the GFP virus were administered to two 11-week-old 
male mice each. After three days, we sacrificed the mice in order to harvest liver tissue. Whereas there 
was no evidence of mutagenesis in the control mice, the CRISPR-Pcsk9 mice displayed substantial levels 
of mutagenesis, with one of the mice showing ~50% mutagenesis in the Surveyor assay, consistent with 
alteration of at least half of the Pcsk9 alleles in the liver (Figure 1B, Supplemental Figure 1). Analyzing 
liver DNA from that mouse, we found that a wide variety of indels were produced in Pcsk9, ranging from 
1 bp to 228 bp, with the possibility of larger indels that were not detected by PCR analysis (Supplemental 
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Figure 1). The most frequent indels were a 1-bp insertion and a 2-bp deletion. We assessed for off-target 
mutagenesis at the 10 sites deemed most closely matched to the on-target site and most likely to harbor 
off-target effects (six sites with three mismatches to the on-target site and the four highest-scoring sites 
with four mismatches to the on-target site; see Online Supplement for site sequences). We found no 
evidence of significant off-target mutagenesis, within the limit of detection by the Surveyor assay (Figure 
1D). 
 
We next performed a more comprehensive experiment in which the CRISPR-Pcsk9 virus and the GFP 
virus were administered to five 5-week-old female mice each, with an additional group of five mice 
receiving no virus. After four days, the CRISPR-Pcsk9 mice all displayed substantial levels of 
mutagenesis, in some cases exceeding 50%, with no mutagenesis observed in any of the mice in the two 
control groups (Figure 1C). We compared plasma PCSK9 levels at four days by enzyme-linked 
immunosorbent assay (ELISA); the CRISPR-Pcsk9 mice displayed substantially lower PCSK9 levels 
compared to each of the control groups of mice [2597 pg/mL with CRISPR-Pcsk9 virus vs. 26461 pg/mL 
with GFP virus (P = 0.0079) and vs. 21734 pg/mL with no virus (P = 0.0079); N = 5 per group; Figure 
2A]. 
 
Whereas there was no significant difference in plasma triglyceride levels among the three groups at four 
days, CRISPR-Pcsk9 mice had significantly lower levels of total plasma cholesterol, with 35%–40% 
reduction compared to the control groups [101 mg/dL with CRISPR-Pcsk9 virus vs. 157 mg/dL with GFP 
virus (P = 0.0079) and vs. 161 mg/dL with no virus (P = 0.0079); N = 5 per group; Figure 2A]. We 
performed complete lipoprotein profiling of pooled plasma samples from each group, observing reduced 
HDL and LDL fractions in CRISPR-Pcsk9 mice (Figure 2B), consistent with prior observations in Pcsk9 
knockout mice.9 No significant difference in blood ALT levels at four days among the three groups was 
observed, and hematoxylin/eosin staining of liver sections from representative mice that received either 
the GFP virus or the CRISPR-Pcsk9 virus showed no inflammation (Figure 2C). Finally, we assessed 
LDLR levels in liver by Western blot analysis. PCSK9 functions to downregulate LDLR;9 consistent with 
this relationship, the CRISPR-Pcsk9 mice had higher levels of LDLR protein than the control groups of 
mice (Figure 2D). 
 
DISCUSSION 
 
In this proof-of-principle study, we found that CRISPR-Cas9 could disrupt the mouse Pcsk9 gene in vivo 
with high efficiency and result in decreased circulating PCSK9 levels, increased hepatic LDLR levels, 
and decreased plasma cholesterol levels. The 35%–40% lower cholesterol levels in the CRISPR-Pcsk9 
mice compared to control mice is consistent with the 36%–52% lower levels previously observed in 
Pcsk9 knockout mice compared to wild-type mice.9 Thus, this approach may have therapeutic potential 
for the prevention of cardiovascular disease in humans. 
 
Although the use of adenovirus allows for efficient delivery to the liver and sustained expression of the 
CRISPR-Cas9 system, it is not the optimal therapeutic vehicle due to the immune response to the virus. 
Indeed, inflammation and acute phase responses could potentially have affected the plasma cholesterol 
levels in the mice receiving adenovirus. However, we included a control group that did not receive any 
adenovirus, and the plasma PCSK9, triglyceride, cholesterol, and ALT levels were very similar to the 
levels observed in the control group that received the GFP virus. There was no apparent inflammation in 
the liver within the time frame of the experiments. Thus, we did not see any evidence of confounding due 
to the use of adenovirus. 
 
While the use of adeno-associated virus would be preferable, the gene encoding Streptococcus pyogenes 
Cas9 (~4.2 kb) in combination with a CRISPR guide RNA-expressing cassette (~500 bp) is too large to fit 
into standard liver-targeting adeno-associated virus vectors (e.g., AAV2/8). Furthermore, the rapidity with 
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which robust alteration of the Pcsk9 gene occurred in our experiments—up to >50% mutagenesis in just 
three to four days—suggests that a single brief pulse of CRISPR-Cas9 expression would be sufficient to 
achieve a therapeutic effect. Thus, a virus-free delivery method that transiently expresses CRISPR-Cas9 
(e.g., RNAs in lipid nanoparticles) might be optimal. A recent study showed that hydrodynamic tail vein 
injection of DNA vectors encoding CRISPR-Cas9 successfully targeted a liver gene (Fah) with no 
apparent long-term adverse effects.10 
 
A possible barrier to therapeutic CRISPR-Cas9 applications is the issue of off-target mutagenesis. In our 
study, we did not observe significant off-target mutagenesis at a number of potential off-target sites, but 
we cannot rule out low-frequency events in vivo. Strategies to greatly reduce off-target mutagenesis 
without impairing on-target mutagenesis are being developed and can be adapted for use in therapeutic 
applications. 
 
With cardiovascular disease being the number one killer worldwide, a safe and effective PCSK9-genome-
editing therapy could have a significant impact on human health. A single administration could confer the 
benefits of naturally occurring PCSK9 loss-of-function mutations—a permanent reduction in LDL-C 
levels and CHD risk, equivalent to taking statins every day for the rest of one’s life but without the need 
for chronic therapy. It could represent a paradigm shift in thinking about cardiovascular therapeutics: a 
one-shot, long-term solution—not unlike a vaccination—rather than a pill to be taken every day or an 
injection to be received every few weeks. It could also open the door to a whole new class of therapies, 
where one might be able to target not just PCSK9 but a number of other potential therapeutic genes; 
indeed, given the multiplexing capacity of CRISPR-Cas9,7,8 it might be feasible to efficiently target 
multiple genes simultaneously with a single therapy. 
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Figure 1. On-target and off-target effects in mouse cells and livers receiving CRISPR-Cas9. A 
shows Surveyor assays performed with genomic DNA from 3T3-L1 cells transfected with Cas9 and a 
guide RNA targeting Pcsk9 exon 1 (gRNA-1) or a guide RNA targeting Pcsk9 exon 2 (gRNA-2). B 
shows Surveyor assays performed with genomic DNA from liver samples taken from mice three days 
after receiving a control adenovirus expressing GFP (A, B) or an adenovirus expressing Cas9 and gRNA-
1 (CRISPR-Pcsk9) (C, D). C shows Surveyor assays performed with genomic DNA from liver samples 
taken from mice four days after receiving no virus (1–5), the GFP virus (6–10), or the CRISPR-Pcsk9 
virus (11–15). D shows Surveyor assays performed with liver genomic DNA from “A” and “C” mice. 
The Pcsk9 exon 1 on-target site and ten genomic sites deemed to be the most likely off-target sites for 
CRISPR-Cas9 activity (OT1–OT10; see Online Supplement for site sequences) were assessed. Arrows 
show the cleavage products resulting from the Surveyor assays; the intensity of the cleavage product 
bands relative to the uncleaved product band corresponds to the mutagenesis rate. 
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Figure 2. Effects of CRISPR-Cas9 genome editing on mice. A shows the results of ELISAs for PCSK9 
protein, measurements of triglyceride levels, and measurements of total cholesterol levels in plasma 
samples from mice four days after receiving no adenovirus, GFP adenovirus, or CRISPR-Pcsk9 
adenovirus (N = 5 mice for each group). B shows the full plasma lipoprotein cholesterol profiles of 
pooled plasma samples from each group of mice. C shows the plasma ALT levels in mice four days after 
receiving virus (N = 5 mice for each group) and hematoxylin/eosin stains of liver sections from 
representative mice. D shows the results of Western blot analysis of liver samples taken from mice four 
days after receiving virus. For A and C, P values were determined by the Kruskal-Wallis test among all 
three groups (in red); if statistically significant, the Mann-Whitney U test between each pair of groups 
was performed (P values in black). Error bars show s.e.m. 
	   CIRCRES/2014/304351DR2  9  
ONLINE SUPPLEMENT 
 
DETAILED METHODS 
 
Screening of guide RNAs 
 
Candidate guide RNAs were designed by visual inspection of the sequences of exons 1 and 2 of the Pcsk9 
gene. Protospacers corresponding to the guide RNAs were inserted into gRNA_Cloning Vector (Dr. 
George Church, http://www.addgene.org/41824/) as previously described.11 Each guide RNA plasmid 
was co-transfected with pCas9_GFP (http://www.addgene.org/44719/) into mouse 3T3-L1 cells with 
TransIT-2020 Reagent (Mirus Bio) according to the manufacturer’s instructions. After 2 days, the cells 
were subjected to fluorescent activated cell sorting (FACSAria II; BD Biosciences) to isolate green 
fluorescent protein (GFP)-positive cells. Genomic DNA was extracted from the isolated cells using the 
DNeasy Blood & Tissue Kit (QIAGEN), and Pcsk9 exon 1 and exon 2 were PCR amplified. The PCR 
products were purified, analyzed using the Surveyor Mutation Detection Kit (Transgenomic) according to 
the manufacturer’s instructions, and run on ethidium bromide-stained 1.5% agarose gels. The guide RNA 
showing the higher mutagenesis rate (exon 1) was chosen for further studies. 
 
Generation of adenoviruses 
 
The protospacer corresponding to the selected guide RNA was inserted into the pX330 plasmid (Dr. Feng 
Zhang, http://www.addgene.org/42230/) that coexpresses the guide RNA and Cas9, as previously 
described.16 The coexpression cassette was cut out of the pX330 plasmid with AflIII and NotI and 
subcloned into the pShuttle vector (Clontech) cut with NcoI and NotI. A corresponding pShuttle vector 
with GFP was used as a control. In either case, the expression cassettes were then cut out of pShuttle with 
I-CeuI and PI-SceI and subcloned into the Adeno-X vector (Clontech) cut with the same enzymes. The 
Penn Vector Core at the University of Pennsylvania used these vectors to generate recombinant 
adenoviral particles (designated GFP and CRISPR-Pcsk9). 
 
Animal studies 
 
All procedures used in animal studies were approved by the pertinent Institutional Animal Care and Use 
Committees at the University of Pennsylvania and Harvard University and were consistent with local, 
state, and federal regulations as applicable. A total of four 11-week-old male C57BL/6 mice were 
simultaneously used for the first experiment, two each for the GFP and CRISPR-Pcsk9 adenoviruses. A 
total of 15 5-week-old female C57BL/6 mice were simultaneously used for the second experiment, five 
each for the GFP and CRISPR-Pcsk9 adenoviruses and five with no virus. Mice were administered 2.5 × 
1010 particles each via retro-orbital injection. After three or four days, the mice were sacrificed by carbon 
dioxide asphyxiation after overnight fasting. Whole liver samples were harvested and split for DNA 
analysis, hematoxylin/eosin staining, and/or Western blot analysis, and terminal blood samples were 
collected. 
 
Enzyme-linked immunosorbent assays (ELISAs), measurement of plasma analytes, and Western 
blot analysis 
 
ELISAs were performed on mouse plasma samples using the Mouse Proprotein Convertase 9/PCSK9 
Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions. Triglyceride and 
total cholesterol levels were measured using Infinity Triglycerides Reagent and Infinity Cholesterol 
Reagent (Thermo Fisher) independently according to the manufacturer’s instructions. Pooled plasma from 
each experimental group (150 µL for each group) was separated by FPLC gel filtration. Cholesterol plate 
assays were performed on FPLC fractions using the Infinity Cholesterol Reagent. ALT levels were 
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measured using the Alanine Transaminase Activity Assay Kit (Cayman Chemical) according to the 
manufacturer’s instructions. Western blot analysis was performed with liver lysates using antibodies 
against LDLR and against β-actin (Sigma). 
 
On-target and off-target mutagenesis analyses 
 
Liver genomic DNA samples were isolated and subjected to Surveyor assays as described above. To 
further analyze the Pcsk9 exon 1 on-target site, PCR amplicons for the on-target site were subcloned 
using the TOPO TA Cloning Kit with the pCRII-TOPO vector (Thermo Fisher) according to the 
manufacturer’s instructions. Plasmid DNAs obtained from individual bacterial clones were subjected to 
Sanger sequencing; usable sequence data was obtained from ~135 clones. 
 
Off-target sites were predicted using the CRISPR Design server (http://crispr.mit.edu/).16 Ten sites were 
chosen based on either sequence similarity (three-base mismatches) or high scoring (the top-scoring four-
base mismatches), as shown below. There were no sites that were zero-base, one-base, or two-base 
mismatches. 
 
Guide RNA sequence: 
     GGCTGATGAGGCCGCACATGTGG   
top genome-wide off-target sites 
sequence score mismatches label locus 
AGATGAAGGGGCCGCACATGGAG 0.6 4MMs [1:3:7:9] OT1 chr3:-53797274    
CTGTGATGAGGCAGCACATGTGG 0.6 4MMs [1:2:3:13] OT2 chr2:-35727358    
GGGTCATTAGGCAGCACATGAGG 0.6 4MMs [3:5:8:13] OT3 chr15:+27353354   
GAATGATGAAGCCGCACAGGCGG 0.5 4MMs [2:3:10:19] OT4 chr2:-129514031   
GGGTGATGAGGCAGCACAGGCAG 0.4 3MMs [3:13:19] OT5 chr7:-53619772    
GGGTGCTGAGGCCGCACCTGTGG 0.4 3MMs [3:6:18] OT6 chr10:-90187208   
GGCTTATCAAGCCGTACATGAAG 0.4 4MMs [5:8:10:15]  chr10:-43915219   
GGCTCATTTGGCAGCACATGAGG 0.3 4MMs [5:8:9:13]  chr7:-143656909   
GGTTGAAGAGGCCACACATGAAG 0.3 3MMs [3:7:14] OT7 chr2:-154450561   
AGCTGACGTGGCTGCACATGGGG 0.2 4MMs [1:7:9:13]  chr10:+125595116  
GGGTGTGGAGGCAGCACATGTGG 0.2 4MMs [3:6:7:13]  chr17:+51584115   
GACTGATGAGGCCCCACATCTGG 0.2 3MMs [2:14:20] OT8* chr14:+26837439   
GACTGATGAGGCCCCACATCTGG 0.2 3MMs [2:14:20] OT8* chr14:+26697669   
GACTGATGAGGCCCCACATCTGG 0.2 3MMs [2:14:20] OT8* chr14:+26977053   
GGAGCATGAGGCCCCACATGGAG 0.2 4MMs [3:4:5:14]  chr11:+120134262  
GACTGATTATGCCTCACATGCAG 0.2 4MMs [2:8:10:14]  chr15:+43680258   
GGCTGAGGGAGCAGCACATGTGG 0.2 4MMs [7:9:10:13]  chr7:-56244753    
GGATGCTGAGGTCGCACATCCAG 0.2 4MMs [3:6:12:20]  chr1:-170137588   
GGTTGATGAGGCGGCTCATGAGG 0.2 3MMs [3:13:16] OT9 chr2:+165087015   
GTCTGCTGAGTCTGCACATGAGG 0.2 4MMs [2:6:11:13]  chr13:-118529657  
GGCTGATGAAGCTGCACCTGTGG 0.2 3MMs [10:13:18] OT10 chr2:-127603103   
*duplicated region in the annotated mouse genome 
 
Primer sequences 
 
Genomic amplification of on-target sites. Pcsk9 exon 1: 5’, GGAGGACACGTTTTCTGCAT; 3’, 
CTGCTGCTGTTGCTGCTAC. Pcsk9 exon 2: 5’, TGGGAAAATCTGTGATACGC; 3’, 
TGTAGCCTCTGGGTCTCCTC. 
 
Genomic amplification of off-target sites. OT1: 5’, TGTAGCCTCTGGGTCTCCTC; 3’, 
GAATTCTCCCTCGTGAGCTG. OT2: 5’, CAGTTGCAGGGAGAGGAGAC; 3’, 
	   CIRCRES/2014/304351DR2  11  
GGAACTGACCCTACGATCCA. OT3: 5’, GGATTCAATGGCCAGAGCTA; 3’, 
CTCACCTCTAGGGCCGAACT. OT4: 5’, ACCATAGCGCTTCTGGTTGT; 3’, 
TCCTGAAGGAGCTGGAGAAA. OT5: 5’, CGTGCACACACATTCATTCA; 3’, 
CGTCTCATGGTGCATAGTGG. OT6: 5’, TGTTCCTTCTGCCTCTGCTT; 3’, 
CAGCAAAACGATGCTGATGT. OT7: 5’, ATGAGGAAGTGGCATTGGAG; 3’, 
AGGCCAAGGAAGGAATGACT. OT8: 5’, CTTTCAGGCAAAAGCTGACC; 3’, 
TCTCAGACAGGCATGCAGAC. OT9: 5’, GTCAGACCCTGTCTGGAGGA; 3’, 
CAAACTCGGTTCATGTGGTG. OT10: 5’, CTTCCAAGGCAGCATGTGTA; 3’, 
TGTGTCTTCCACTGGAGCAG. 
 
Statistical analyses 
 
Statistical analyses were performed solely for the second experiment. The levels of four plasma 
analytes—PCSK9, triglycerides, total cholesterol, and ALT—were each compared among three groups—
mice that received no virus (N = 5), mice that received GFP virus (N = 5), and mice that received 
CRISPR-Pcsk9 virus (N = 5). Initially, the Kruskal-Wallis test was performed for each of the four 
analytes, with a statistical significance threshold of P < 0.0125 to account for multiple testing (Bonferroni 
correction for four tests). Two analytes (PCSK9 and total cholesterol) were found to reach statistical 
significance. For each of the these two analytes, the Mann-Whitney U test was performed for each 
possible pairwise comparison among the three groups of mice, with a statistical significance threshold of 
P < 0.00833 to account for multiple testing (Bonferroni correction for two sets of three pairwise 
comparisons performed). All statistical analyses were performed using GraphPad Prism 6 for Mac OS X. 
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SUPPLEMENTAL FIGURES 
 
 
 
Supplemental Figure 1. Mutagenesis of Pcsk9 in vivo with CRISPR-Cas9. The CRISPR-Cas9 target 
site in Pcsk9 exon 1 is shown. The boxes indicate the 20-bp sequence matching the protospacer and the 3-
bp PAM. The predicted site of Cas9-induced double-strand breaks is indicated with an arrow. Deletions 
and insertions detected by PCR amplification and Sanger sequencing of the on-target site in liver genomic 
DNA from a representative mouse (“C” in Figure 1) that received an adenovirus expressing Cas9 and the 
guide RNA for the target site (CRISPR-Pcsk9) are shown. At the bottom are deletions that spanned the 
entire site. 
